Clinical Trial Update: Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now

View source ↗

Summary

A registry study update from AstraZeneca on the evolution of lung cancer therapy implementation and outcomes. The study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small-Cell Lung Cancer | Status: TERMINATED